

## Determination of Hemoglobin A<sub>1c</sub> Content by an Automated Hemoglobin Analyzer, HLC-723G7, Myanmar

Ne WIN and Keiko HARANO\*

*Pathology Research Division,  
Department of Medical Research (Lower Myanmar),  
Yangon, Union of Myanmar*

*\*Department of Clinical Nutrition,  
Faculty of Health Science and Technology,  
Kawasaki University of Medical Welfare, Kurashiki 701-0193, Japan*

*Accepted for publication on January 25, 2005*

**ABSTRACT.** The HLC-723G7, an automated hemoglobin analyzer, is fully automatic and results are reproducible. Results are obtained within 90 seconds and printed out. The analyzer has been tested on a total of 120 blood samples from different patient and subject populations. The results obtained were described and discussed. We suggest use of this machine in the management of diabetes and in future research work related to diabetes. Hb A<sub>1c</sub> determination can now be performed at a reasonable cost rapidly, reliable and accurately in Myanmar, an important step towards control of the complications of diabetes and monitoring of diabetic patients under various treatment regimes.

**Key words :** automated hemoglobin analyzer, HLC-723G7 — glycosylated hemoglobin (Hb A<sub>1c</sub>) — diabetes mellitus — hemoglobinopathies — Myanmar

Glycosylated hemoglobin (Hb A<sub>1c</sub>) content is one of the most important laboratory parameters in the management of patients with diabetes mellitus, particularly in case monitoring and assessment.<sup>1)</sup> In Myanmar, where both insulin dependent and non-insulin dependent diabetes mellitus are common, Hb A<sub>1c</sub> can be determined only in a few selected cases due to various constraints. Economic and laboratory factors are the main reasons. Recently a set-up for Hb A<sub>1c</sub> determination has been established in the Pathology Research Division, Department of Medical Research (Lower Myanmar). A preliminary report on the results and findings after the establishment of this laboratory set-up for Hb A<sub>1c</sub> are presented here.

### MATERIALS AND METHODS

An automated hemoglobin analyzer, HLC-723G7 (Tosoh Corporation, Tokyo, Japan) was provided to the Pathology Research Division, Department of Medical Research (Lower Myanmar). It was fully installed and calibrated according to the instruction manual of the manufacturer, Tosoh Corporation.<sup>2)</sup> Calibrator and control reagents were used for

---

ネ ウィン, 原野恵子  
e-mail : haranok@bcc.kawasaki-m.ac.jp

calibration and fresh whole blood samples from apparently healthy persons ( $n=65$ ) and from patients of different clinical entities ( $n=55$ ) were used for test runs. Hb A<sub>1c</sub> content results for one sample were printed out as the percentage of total hemoglobin content in 90 seconds.

After installation and calibration, Hb A<sub>1c</sub> content was determined in various subjects and patients in ongoing projects, some of which are being done in collaboration with Japanese scientists. Subject and patient populations include blood donors, pregnant mothers, normal control subjects from stroke studies and cardiovascular studies, diabetic patients, stroke patients, children with dengue hemorrhagic fever or hemolytic anemias, and patients with different forms of thalassemia or hemoglobinopathies.

Samples which had extremely unexpected Hb A<sub>1c</sub> and Hb F content or questionable Hb peaks underwent isoelectric focusing (IEF; pH range: 6-9) of their hemolysates to confirm the presence of Hbs including abnormal Hb.<sup>3)</sup>

### RESULTS AND FINDINGS

The retention times of Hb F, labile Hb A<sub>1c</sub>, stable Hb A<sub>1c</sub> (Hb A<sub>1c</sub>) and Hb A shown on chromatograms were about 0.5, 0.6, 0.7 and 1.0 minutes, respectively. The time required for the examination of one sample is only 90 seconds (Fig 1). The Hb content is estimated from areas and printed out with the chromatogram.

The Hb A<sub>1c</sub> content of the subjects determined here ranged from 1.0% to 12.2%. The content of subjects, excluding most diabetic patients, whose serum glucose level was not controlled by drugs, exercise or diet treatments, and  $\alpha$ -thalassemic patients with Hb H disease, was within a range from 3.5 to 5.8, which is the normal range in Japan (Table 1 and Fig 2). The Hb




Fig 1. A chromatogram of a blood sample from normal blood donor or the normal volunteer. The Hb F, labile Hb A<sub>1c</sub> and stable Hb A<sub>1c</sub> (Hb A<sub>1c</sub>) contents were 0.5%, 1.8% and 4.1%, respectively. The normal range of Hb A<sub>1c</sub> in Japan is 3.5-5.8%.

TABLE 1. Hb A<sub>1c</sub> content seen in various study population

Patient/Subject	No. of cases	Age range (years)	Hb A <sub>1c</sub> range (%)	Type of sample	Remarks (n)
Blood donors (Fig 1)	18	19-51	3.6-4.5	Fresh	hemolysate
Pregnant mothers	11	29-39	3.6-4.7	Fresh	hemolysate
Stroke (control* <sup>a</sup> )	11	23-70	2.5-5.3	Fresh	whole blood
Stroke (Patient)	11	27-73	3.2-6.8	Fresh	whole blood
CVD (control* <sup>a</sup> )	6	42-57	4.8-5.7	Fresh	whole blood
CVD (Patient)	6	47-63	4.5-6.7	Fresh	whole blood
Diabetics	11	50-70	5.2-12.2	Fresh	under treatment
DHF children	3	1.5-5	4.1-4.7	Old	hemolysate
Thalassemia major	4	1-2.5	1.6-3.5	Fresh	hemolysate
Thalassemia traits (Fig 2, 3)	13	14-33	1.0-9.9	Old	AT(7)* <sup>b</sup> , BT(6)
Hemoglobinopathy (Fig 4)	7	47	3.8-4.8	Fresh	HbE(5); u/k(2)
Volunteers (Fig 1)	15	26-70	4.1-5.5	Fresh	whole blood
Others* <sup>c</sup>	4	u/k	2.5-3.8	Old	hemolysate
Total	120	1-70	1.0-12.2	—	—

Old : old hemolysate using CCl<sub>4</sub>; a questionable abnormal Hb band was seen in a chromatogram

\*<sup>a</sup> : control means under control or under treatment.

\*<sup>b</sup> : an unexpectedly high Hb A<sub>1c</sub> peak appeared in a chromatogram of a patient diagnosed with Hb H disease (Fig 3).

\*<sup>c</sup> : u/k=unknown

CVD=cardiovascular disease

DHF=dengue hemorrhagic fever

AT= $\alpha$ -thalassemia

BT= $\beta$ -thalassemia




Fig 2. A chromatogram obtained from a blood sample of a patient with  $\alpha$ -thalassemia-1. The stable Hb A<sub>1c</sub> content was 5.1%, while the contents of Hb F and labile Hb A<sub>1c</sub> were 2.6% and 1.6%, respectively. That from a well-controlled diabetic patient was similar.

A<sub>1c</sub> content of the diabetic patients under treatment and uncontrolled, on the contrary, was relatively high and that of patients with Hb H disease, which is a severe type of  $\alpha$ -thalassemia, was unexpectedly high (Fig 3). The Hb A<sub>1c</sub> content of patients with the heterozygote for Hb E was relatively low, but there was a small peak suspected to be an abnormal




Fig 3. A chromatogram of a blood sample from a non-diabetic patient diagnosed with Hb H disease, in whom the Hb A<sub>1c</sub> level was at an extremely high level of 9.9%. However, since no abnormal Hb or Hb H peak was observed at any retention time, the Hb peak eluted at the same position as Hb A<sub>1c</sub> was considered to include Hb H.




Fig 4. A chromatogram of a blood sample from a patient having Hb E showed an unexpectedly low Hb A<sub>1c</sub> level, 2.5%. However, as Hb E is characterized by electrophoretically slow-moving behavior, the Hb peak appearing between the Hb A<sub>1c</sub> and Hb A peaks was considered to be a glycosylated Hb E (Hb E<sub>1c</sub>), with a value of 1.8%. Therefore, the glycosylated Hb level of this patient with Hb E was estimated to be 4.3%.




Fig 5. IEF of the hemolysates prepared from patients with various kinds of diseases on polyacrylamide gel (pH range 6-9). The Hb E and Hb H bands were isoelectrofocussed around the Hb A<sub>2</sub> zone and the anodic site to Hb A, respectively. 1: Normal control. 2: Hb E heterozygote. 3: Normal. 4: Hb H disease.

peak between the Hb A<sub>1c</sub> and Hb A peaks (Fig 4). It seemed to be glycosylated Hb E (Hb E<sub>1c</sub>), because as Hb E moves electrophoretically slower than Hb A, Hb E<sub>1c</sub> is considered to be eluted later than Hb A<sub>1c</sub>. The suspected presence of abnormal Hbs; e.g., Hb H and Hb E, that are the most common abnormal Hbs in Myanmar and neighboring countries,<sup>4-6</sup> was confirmed by application of the IEF method to their hemolysates (Fig 5). The Hb A<sub>1c</sub> level of patients with hyperglycemia or uncontrolled serum glucose levels may be higher than 5.8%, while that of non-diabetic patients with Hb H is not considered to go beyond 5.8%, as seen in Fig 3. Based on these results, it was concluded that the Hb H peak is eluted at a position to the Hb A<sub>1c</sub> peak and the Hb E<sub>1c</sub> peak is between the Hb A<sub>1c</sub> and Hb A peaks. Therefore, it is difficult to determine the accurate glycosylated Hb content of a patient with Hb H or Hb E disease accurately with only the HLC-723G7. To make a decision requires the data from a complete blood cell count, Hb analysis, Hb biosynthesis, and red cell morphology.

The Hb A<sub>1c</sub> content in various study populations is shown in Table 1.

#### DISCUSSION

The automated hemoglobin analyzer, HLC-723G7, has been well known in Japan<sup>7,8)</sup> and worldwide, but particularly in Asian and Southeast Asian nations during the last few years for its accurate determination of Hb A<sub>1c</sub> and Hb A<sub>2</sub> content. Whole blood or hemolysate is used and elution time and total area exposed to individual hemoglobin are recorded and printed out as the percentage of total hemoglobin (Fig 1).

The machine has been used effectively for the determination of Hb A<sub>1c</sub> in 120 samples since its successful installation and establishment. The minimal and maximal Hb A<sub>1c</sub> values obtained have been 1% and 12.2%, respectively, varying with the subject population under study (Table 1).

Among apparently healthy volunteers and blood donors, the Hb A<sub>1c</sub> level has ranged from 3.6% to 5.5% (Table 1). They have had no detectable abnormal hemoglobin or thalassemia. Therefore, this value can be taken as the normal Hb A<sub>1c</sub> level in the Myanmar population. In a previous study of diabetic patients in Mandalay, Myanmar, the whole glycosylated hemoglobin concentration (Hb A<sub>1</sub> = labile Hb A<sub>1c</sub> + stable Hb A<sub>1c</sub>) content for the control subjects was  $2.2 \pm 0.5\%$  and that for the diabetic patients was  $6.4 \pm 3.6\%$ .<sup>9,10</sup> In that study the phenol-sulphuric acid method was used. In Japan the normal Hb A<sub>1c</sub> value ranges from 3.5% to 5.8%.

The Hb A<sub>1c</sub> level tends to be lower in patients with the  $\alpha$ -thalassemia syndromes,  $\alpha$ -thalassemia-2 and  $\alpha$ -thalassemia-1. Many cases of  $\beta$ -thalassemia and  $\alpha$ -thalassemia-1 have Hb A<sub>1c</sub> content within the normal range (3.4-5.2%) (Fig 2). Hb A<sub>1c</sub> content is sometimes much reduced in thalassemia major cases, ranging from 1% to 3.5%. No significant reduction in glycosylated Hb content was observed in Hb E carriers (Fig 4), because Hb E<sub>1c</sub> is eluted between the Hb A<sub>1c</sub> and Hb A peaks, being estimated as Hb A<sub>1c</sub> plus Hb E<sub>1c</sub>. There was also no significant difference in the Hb A<sub>1c</sub> value between stroke or cardiovascular disease patients and controls. In diabetics, the value spread over a wide range, 5.2-12.2% (Table 1). In pregnant mothers the value was within a normal range, 3.6-4.7%.

There are many advantages to use of the HLC-723G7 for the determination of Hb A<sub>1c</sub>. Only a very minute amount of blood is required (10  $\mu$ l or less is sufficient). Any form of anticoagulant can be used. The hemolysates used can easily be prepared using distilled water or washing buffer provided together with other reagent solutions.<sup>2</sup> The result is readily obtained in 90 seconds and printed out. It is also relatively more economical, less laborious, and more rapid than other methods such as the ion exchange resin chromatography, affinity chromatography or biochemical colorimetric assays.<sup>11-14</sup>

In conclusion, the HLC-723G7 is most suitable for determining Hb A<sub>1c</sub> in the management of diabetes and in future research work related to diabetes, since it has many advantages over other methods. We have planned some clinical field and laboratory-based research projects on diabetes using this analyzer to begin in the very near future. The common limitations to the determination of Hb A<sub>1c</sub> content have been overcome by the development of a set-up locally in Department of Medical Research (Lower Myanmar).

#### ACKNOWLEDGMENT

We wish to thank Mr. Alvin Chan, Sysmex Singapore PTE Ltd., for his enthusiastic technical assistance and Mrs. Myat Mon Oo and Miss. Khin Myo Sett for the determination of isoelectric focusing of hemolysates.

#### REFERENCES

- 1) Bunn HF, Gorget BG: *Hemoglobin: Molecular, Genetic and Clinical Aspects*. 74-82, W.B. Saunders Company, Philadelphia, 1986
- 2) Manufacturer's instruction manuals. Automated hemoglobin analyzer. Tosoh Co.

- Japan, 2004
- 3) Harano T, Harano K, Koide T, Okada M, Ueda S, Shibata S: Mass screening method for abnormal hemoglobin by isoelectric focusing. *Jpn J Clin Pathol* **28**: 149-152, 1980
  - 4) Harano T, Ne Win, Harano K: Prevalence of hemoglobin E among the children taking regular blood transfusion at the day care room, Yangon Children Hospital, Myanmar. *Kawasaki Med J* **26**: 149-154, 2000
  - 5) Fucharoen S, Winichagoon P, Piankijagum A: Standardization on laboratory diagnosis of thalassemia and abnormal hemoglobin. *Southeast Asian J Trop Med Public Health* **30**: 90-98, 1999
  - 6) Harano T, Ne Win, Harano K: Molecular aspects of  $\alpha$ -thalassemia in Myanmar. *Kawasaki Med J* **27**: 33-36, 2001
  - 7) Harano T, Harano K, Tin YY, Suetsugu Y, Sutcharichan P, Settapiboon R, Tashiro H, Uchida J: An automated Hb A<sub>2</sub> analyzer, HLC-723G7, for diagnosis of thalassemias. *Proceeding of the 22<sup>nd</sup> world congress of Pathology and Laboratory Medicine*, 203-206, Busan, Korea, August 30-September 3, 2003
  - 8) Sutcharitchan P, Settapiboon R, Amornsiriwat S, Harano T: Evaluation of automated glycohemoglobin analyzer HLC-723G7  $\beta$ -thalassemia analysis mode. *Lab Hematol* **10**: 32-37, 2004
  - 9) Brena RK, Sherma KK, Pathabiraman TN.: Short duration colorimetric method based on phenol-sulphuric acid reaction for estimation of glycosylated Hb. *Biochem Med* **31**: 65-72, 1984
  - 10) Khin Ye Myint, Than Than Kyaing.: A study of Hb A<sub>1c</sub> in diabetics of Mandalay General Hospital. *The Myanmar Health Sciences Research Journal* **9**: 110-116, 1993
  - 11) Garlick RL, Mazer JS, Higgins PJ, Bunn HF: Characterization of glycosylated hemoglobins. Relevance to monitoring of diabetic control and analysis of other proteins. *J Clin Invest* **71**: 1062-1072, 1983
  - 12) Shapiro R, McManus M, Garrick L, McDonald MJ, Bunn HF: Nonenzymatic glycosylation of human hemoglobin at multiple sites. *Metabolism* **28**: 427-430, 1979
  - 13) John WG, Albutt EC, Handley G, Richardson RW: Affinity chromatography method for the measurement of glycosylated haemoglobin: comparison with two methods in routine use. *Clin Chim Acta* **31**: 257-262, 1984
  - 14) Fischer RW, De Jong C, Voigt E, Berger W, Winterhalter KH: The colorimetric determination of Hb A<sub>1c</sub> in normal and diabetic subjects. *Clin Lab Haematol* **2**: 129-138, 1980